Factsheet H1/20

COMPANY PROFILE

Fresenius is a global health care group providing products and services for dialysis, hospitals and outpatient medical care. In addition, Fresenius focuses on hospital operations. We also manage projects and provide services for hospitals and other health care facilities. More than 302,000 employees have dedicated themselves to the service of health in over 100 countries worldwide.

FRESENIUS GROUP IN FIGURES

€ in millions | H1/20 | H1/19 | Change | FY/19
--- | --- | --- | --- | ---
Sales and Earnings
Sales | 18,055 | 17,256 | 5% | 35,409
EBIT | 2,248 | 2,248 | 0% | 4,688
Net income | 875 | 928 | -6% | 1,879
Earnings per ord. share in € | 1.57 | 1.67 | -6% | 3.37
Balance sheet and cash flow
Total assets | 69,554 | 67,006 | 4% | 67,006
Non-current assets | 52,401 | 51,742 | 1% | 51,742
Equity | 27,252 | 26,580 | 3% | 26,580
Equity ratio | 39.2% | 39.7% | - | 39.7%
Net debt/EBITDA | 3.39 | 3.61 | - | 3.61
Investments | 1,530 | 3,163 | -52% | 5,086
Operating cash flow | 3,960 | 1,494 | - | 4,263
Operating cash flow in % of sales | 21.9% | 8.7% | - | 12.0%
Profitability
EBIT margin | 12.5% | 13.0% | - | 13.2%
Return on equity after taxes (ROE) | 10.5% | 11.7% | - | 11.2%
Return on operating assets (ROOA) | 7.4% | 7.8% | - | 7.6%
Return on invested capital (ROIC) | 6.6% | 6.9% | - | 6.7%
Employees | 302,846 | 294,134 | - | -

1 As of June 30, 2020
2 Before special items
3 Net income attributable to shareholders of Fresenius SE & Co. KGaA
4 Including noncontrolling interests
5 LTM average exchange rates for both net debt and EBITDA
6 pro forma closed acquisitions/divestitures
7 Investments in property, plant and equipment, and intangible assets, acquisitions

BUSINESS SEGMENTS

The operating business comprises the four business segments Fresenius Medical Care, Fresenius Kabi, Fresenius Helios and Fresenius Vamed, all of which are legally independent entities managed by the operating parent company Fresenius SE & Co. KGaA.

- Fresenius Medical Care is the world’s largest provider of products and services for individuals with renal diseases. As of June 30, 2020 Fresenius Medical Care was treating 347,683 patients in 4,036 dialysis clinics. Along with its core business, the company provides related medical services in the field of Care Coordination.
- Fresenius Kabi offers intravenously administered generic drugs, clinical nutrition and infusion therapies for seriously and chronically ill patients. The company is also a leading supplier of medical devices and transfusion technology products. In the biosimilars business, Fresenius Kabi develops products with a focus on oncology and autoimmune diseases.
- Fresenius Helios is Europe’s leading private hospital operator. Helios Germany operates 86 hospitals, ~125 outpatient centers and 6 prevention centers. Quirónsalud operates 46 hospitals, 70 outpatient centers and around 300 occupational risk prevention centers. In addition, the company is active in Latin America with 6 hospitals.
- Fresenius Vamed manages projects and provides services for hospitals and other health care facilities worldwide and is a leading post-acute care provider in Central Europe. The portfolio ranges along the entire value chain: from project development, planning, and turnkey construction, via maintenance and technical management to total operational management.

SALES BY BUSINESS SEGMENT

Fresenius Vamed 5%
Fresenius Kabi 19%
Fresenius Helios 26%
Fresenius Medical Care 50%

SALES BY REGION

<table>
<thead>
<tr>
<th>Region</th>
<th>H1/20: €18.1 billion</th>
</tr>
</thead>
<tbody>
<tr>
<td>North America</td>
<td>43%</td>
</tr>
<tr>
<td>Latin America</td>
<td>5%</td>
</tr>
<tr>
<td>Asia-Pacific</td>
<td>9%</td>
</tr>
<tr>
<td>Europe</td>
<td>43%</td>
</tr>
<tr>
<td>Others</td>
<td>5%</td>
</tr>
</tbody>
</table>

Factsheet H1/20 © Fresenius SE & Co. KGaA – Investor Relations & Sustainability
FRESENIUS SHARE / ADR

<table>
<thead>
<tr>
<th>Securities code no.</th>
<th>578 560</th>
</tr>
</thead>
<tbody>
<tr>
<td>ISIN</td>
<td>DE0005785604</td>
</tr>
<tr>
<td>Ticker symbol</td>
<td>FRE</td>
</tr>
<tr>
<td>ADR CUSIP</td>
<td>35804M105</td>
</tr>
<tr>
<td>ADR Ticker symbol</td>
<td>FSNUY</td>
</tr>
<tr>
<td>Number of shares (June 30, 2020)</td>
<td>557,453,784</td>
</tr>
<tr>
<td>Market capitalization (June 30, 2020)</td>
<td>€24.6 billion</td>
</tr>
</tbody>
</table>

SHARE PERFORMANCE ¹

- 30%  
- 7%  
- 41%  
- 23%  
+ 143%

¹ Effective date/closing price: June 30, 2020

FINANCING MIX OF THE FRESENIUS GROUP

- Equity-neutral convertible bonds 2%
- Other financial liabilities 3%
- Commercial papers 5%
- Schuldschein loans 7%
- Syndicated loans 12%

According to IFRS 16

GROUP OUTLOOK 2020 (including estimated COVID-19 effects)

<table>
<thead>
<tr>
<th>€m (except otherwise stated)</th>
<th>FY’19 Base¹</th>
<th>Targets 2020 ³</th>
</tr>
</thead>
<tbody>
<tr>
<td>Sales, growth (cc)</td>
<td>35,409</td>
<td>+3% to +6%</td>
</tr>
<tr>
<td>Net income ¹ , growth (cc)</td>
<td>1,879</td>
<td>-4% to +1%</td>
</tr>
</tbody>
</table>

¹ Before special items, including IFRS 16 effect, excluding NxStage operations
³ Before special items
³ Including estimated COVID-19 effects

For the outlook of the business segments please see the Investor News of July 30, 2020.

FINANCIAL CALENDAR

Virtual Annual General Meeting 2020: August 28, 2020
Report on 1st – 3rd quarter 2020: October 29, 2020

Please note that these dates could be subject to modifications.

CONTACT

Fresenius SE & Co. KGaA
Else-Kröner-Straße 1, 61352 Bad Homburg v. d. H.
e-mail: ir-fre@fresenius.com
Internet: www.fresenius.com

Markus Georgi
Senior Vice President
Investor Relations & Sustainability
Telephone: +49 61 72 6 08-24 85
Telefax: +49 61 72 6 08-24 88

Follow us on twitter and linkedin